clinical trial · NCT07287436
Elite AF IDE Trial (Elite AF)
Atrial Fibrillation (AF)StrokeWATCHMAN Elite LAAC Device
brief summary
The primary objective of this study is to establish the safety and effectiveness of the WATCHMAN Elite Left Atrial Appendage Closure (LAAC) Device for subjects with non-valvular atrial fibrillation who are eligible for anticoagulation therapy to reduce the risk of stroke.
started
Sep 18, 2026
primary completion
Jan 1, 2028
completion
Nov 1, 2032
last updated
Nov 20, 2026
detailed description
This study is a prospective, non-randomized, multicenter investigation to establish the safety and effectiveness of the WATCHMAN Elite LAAC Device for subjects with non-valvular atrial fibrillation who are suitable for anticoagulation therapy to reduce the risk of stroke but who have a rationale to seek a non-pharmacologic alternative.
official title
Investigational Device Evaluation of the WATCHMAN Elite™ Left Atrial Appendage Closure Technology
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol